Publication: Neoadjuvant hormonal therapy in breast cancer
Program
KU-Authors
KU Authors
Co-Authors
Selcukbiricik, Fatih
Publication Date
Language
Type
Embargo Status
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
The various types of ER-positive and HER-2-negative breast cancers have different treatment modalities. There are two options for the treatment of locally advanced breast cancer: chemotherapy or hormonal therapy. Chemotherapy can be particularly toxic for elderly postmenopausal patients, and neoadjuvant hormonal therapy (NHT) is an alternative for patients with hormone receptor-positive, locally advanced, postmenopausal breast cancer. This treatment is also highly beneficial for patients with comorbidities and can comprise tamoxifen and steroidal or nonsteroidal aromatase inhibitors (AIs). The best activities in clinical trials are observed with AIs. NHT produces good response rates (RRs) as well as adequate downstaging of tumor size such that breast-conserving surgery (BCS) may become an option. The optimal duration of such treatments should not be less than 4 months and may be continued for as long as 8 months.
Source
Publisher
Springer
Subject
Oncology
Citation
Has Part
Source
Breast Disease: Management and Therapies
Book Series Title
Edition
DOI
10.1007/978-3-319-26012-9_14